Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician ...

Regeneron Pharmaceuticals announced that the FDA has accepted the resubmission of its Biologics License Application (BLA) for linvoseltamab, an investigational treatment for adult patients with ...

(RTTNews) - Regeneron Pharmaceuticals, Inc. (REGN) Tuesday said that the resubmission of Biologics License Application (BLA) for linvoseltamab for the treatment of multiple myeloma has been ...

Emily Davies covers the federal government's impact in the D.C. area. Send her secure tips on Signal at emilydavies.46 Education: Brown University, B.A. Emily Davies is a reporter covering the ...

Using CytomX’s Probody and Regeneron’s Veloci-Bi platforms, the collaboration and licensing agreement aims to enable the development of investigational next-generation bispecific immunotherapies.

TARRYTOWN, N.Y., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows: TD Cowen 45th Annual Health Care Conference at ...

AZ and Regeneron will collaborate on finding small-molecule drugs directed against the GPR75 target, splitting the costs of the programme and sharing any resulting profits from the endeavour.

Emily Stewart is a senior correspondent at Business Insider, writing about business and the economy. Previously, she worked at Vox and TheStreet. Companies are demanding workers return to the ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...